GlassScriptPhysician profile
Howard L Brooks
NPI 1568687739
$8,797.87
in general payments reported to CMS, 2019-2025
31 companies · $1,672 in 2025
The $1,672 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $223 · 2021: $1,079 · 2022: $1,224 · 2023: $1,876 · 2024: $2,518 · 2025: $1,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,737 · Education: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,737.14 |
| Education | $328.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,406.60 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $1,182.64 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $944.39 | 2021-2025 | |
| Genzyme Corporation | $786.01 | 2020-2025 | |
| Lilly USA, LLC | $656.42 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $546.88 | 2023-2024 | Vtama |
| Leo Pharma INC. | $434.36 | 2022-2025 | Adbry, Anzupgo |
| Incyte Corporation | $404.55 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $368.81 | 2022-2024 | Sotyktu |
| Pfizer INC. | $318.51 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $313.94 | 2020-2025 | Dupixent, Libtayo |
| Ucb, INC. | $274.79 | 2021-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $213.27 | 2022-2025 | Ilumya, Odomzo, Blu-U |
| Organon LLC | $132.47 | 2023-2025 | Vtama, Hadlima |
| Biofrontera INC. | $112.01 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $104.07 | 2023-2024 | Zoryve |
| Galderma Laboratories, L.P. | $95.08 | 2019-2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $92.00 | 2024 | |
| Vyne Pharmaceuticals INC. | $67.53 | 2020-2021 | |
| Amgen INC. | $63.09 | 2020-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.68 | 2019-2021 | |
| Almirall LLC | $40.58 | 2019-2025 | Klisyri |
| Journey Medical Corporation | $35.52 | 2019-2023 | |
| Medimetriks Pharmaceuticals, INC. | $24.74 | 2024 | Neo-Synalar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.92 | 2022 | |
| Mayne Pharma Commercial LLC | $18.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.75 | 2022 | |
| Dermira, INC. | $18.22 | 2021 | |
| Merz North America, INC. | $17.67 | 2019 | |
| Nabriva Therapeutics, Plc | $17.64 | 2020 | |
| Encore Dermatology INC. | $15.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.